Lake Street analyst Brooks O’Neil initiated coverage of Beta Bionics (BBNX) with a Buy rating and $30 price target Beta’s iLet Bionic Pancreas offers “groundbreaking simplicity for patients, caregivers, and doctors,” says the analyst, who believes Beta is in the early stages of the development of a differentiated patch pump and a first-of-its-kind bihormonal configuration of the iLet. These two projects are unlikely to reach the U.S. market before late 2027, but the firm sees “significant potential for both pumps,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics initiated with an Outperform at Leerink
- Beta Bionics initiated with an Overweight at Piper Sandler
- Beta Bionics initiated with a Buy at Stifel
- Buy Recommendation for Beta Bionics: Leveraging Untapped Market Opportunities and Innovative Product Differentiation
- Palantir initiated, Roku upgraded: Wall Street’s top analyst calls